Next Article in Journal
Impact of Genomic Mutation on Melanoma Immune Microenvironment and IFN-1 Pathway-Driven Therapeutic Responses
Previous Article in Journal
Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 16
Issue 14
10.3390/cancers16142569
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Systematic Review and Meta-Analysis of Particle Beam Therapy versus Photon Radiotherapy for Skull Base Chordoma: TRP-Chordoma 2024

by
Takashi Saito
1,
Masashi Mizumoto
1,*,
Yoshiko Oshiro
2,
Shosei Shimizu
3,
Yinuo Li
1,
Masatoshi Nakamura
1,
Sho Hosaka
4,
Kei Nakai
1,
Takashi Iizumi
1,
Masako Inaba
4,
Hiroko Fukushima
4,5,
Ryoko Suzuki
4,5,
Kazushi Maruo
6 and
Hideyuki Sakurai
1
1
Department of Radiation Oncology, University of Tsukuba, Tsukuba 305-8576, Ibaraki, Japan
2
Department of Radiation Oncology, Tsukuba Medical Center Hospital, Tsukuba 305-8558, Ibaraki, Japan
3
Department of Pediatric Radiation Therapy Center/Pediatric Proton Beam Therapy Center, Hebei Yizhou Cancer Hospital, Zhuozhou 072750, China
4
Department of Pediatrics, University of Tsukuba Hospital, Tsukuba 305-8575, Ibaraki, Japan
5
Department of Child Health, Institute of Medicine, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan
6
Department of Biostatistics, Institute of Medicine, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(14), 2569; https://doi.org/10.3390/cancers16142569
Submission received: 22 May 2024 / Revised: 18 June 2024 / Accepted: 8 July 2024 / Published: 17 July 2024
(This article belongs to the Section Systematic Review or Meta-Analysis in Cancer Research)
Browse Figures
Review Reports Versions Notes

Abstract

:

Simple Summary

Chordoma is a rare cancer that often occurs at the base of the skull. Treating skull base chordoma is challenging because the tumor is difficult to completely remove with surgery and has low radiosensitivity. This study compared two types of radiation modality: particle beam therapy (PT) and photon radiotherapy (RT). We found that PT provides better progression-free survival compared to photon RT. However, PT also has a higher risk of causing brain necrosis. Our findings suggest that PT is more effective for controlling skull base chordoma, but careful planning is needed to minimize side effects.

Abstract

[Objective] The aim of this study was to compare the efficacy of particle beam therapy (PT) with photon radiotherapy (RT) for treatment of skull base chordoma. [Methods] A systematic review was conducted for skull base chordoma treated with PT or photon RT reported from 1990 to 2022. Data were extracted for overall survival (OS) and progression-free survival (PFS), late adverse events, age, gender, gross total resection (GTR) rates, tumor volume, total irradiation dose, and treatment modality. Random-effects meta-regression analysis with the treatment modality as an explanatory variable was performed for each outcome to compare the modalities. [Results] A meta-analysis of 30 selected articles found 3- and 5-year OS rates for PT vs. photon RT or combined photon RT/proton beam therapy (PBT) of 90.8% (95% CI: 87.4–93.3%) vs. 89.5% (95% CI: 83.0–93.6%), p = 0.6543; 80.0% (95% CI: 75.7–83.6%) vs. 89.5% (95% CI: 83.0–93.6%), p = 0.6787. The 5-year PFS rates for PT vs. photon RT or photon RT/PBT were 67.8% (95% CI: 56.5–76.7%) vs. 40.2% (95% CI: 31.6–48.7%), p = 0.0004. A random-effects model revealed that the treatment modality (PT vs. photon RT or photon RT/PBT) was not a significant factor for 3-year OS (p = 0.42) and 5-year OS (p = 0.11), but was a significant factor for 5-year PFS (p < 0.0001). The rates of brain necrosis were 8–50% after PT and 0–4% after photon RT or photon RT/PBT. [Conclusion] This study shows that PT results in higher PFS compared to photon RT for skull base chordoma, but that there is a tendency for a higher incidence of brain necrosis with PT. Publication and analysis of further studies is needed to validate these findings.

1. Introduction

Chordoma is a rare disease, with an incidence of 0.18 to 0.84 per million people [1]. The common sites of occurrence are the sacrum and skull base, followed by the spine [1]. NCCN guidelines recommend surgical resection as standard treatment, with postoperative radiation recommended for cases in which residual disease is suspected [2]. However, treatment of chordoma presents significant challenges because complete resection is difficult in common regions of the disease, such as the sacrum and skull base, and the tumor is resistant to radiotherapy (RT) and chemotherapy, which complicates the achievement of local control [3,4]. The prognosis for cases with complete resection is significantly better compared to those with incomplete resection [5,6]. Postoperative RT is useful for skull base chordoma, but a high dose of over 65 Gy is required for local control because of the low radiosensitivity [6]. Thus, advanced irradiation techniques are needed to deliver high doses to the tumor while sparing critical organs such as the brainstem and optic nerves.
Particle beam therapy (PT) is frequently used for skull base chordoma due to its high dose concentration [7]. However, while meta-analyses have shown superiority of PT over photon RT for chordomas in general, no meta-analysis has compared PT to photon RT for skull base chordoma [8]. Compared to chordomas in the sacrum or spine, skull base chordomas are characterized by a younger age of onset, difficulty achieving complete resection due to surrounding anatomical structures, and a greater need for postoperative RT [9,10]. Furthermore, skull base chordomas are often treated similarly to skull base chondrosarcomas. However, chondrosarcomas have higher radiosensitivity and clearly superior survival and local control rates compared to chordomas [11]. While several meta-analyses have compared PT and photon RT for skull base chordomas and chondrosarcomas, it is unclear if these results can be directly extrapolated to skull base chordomas [12,13]. To address these issues, we extracted literature on treatment outcomes and background factors for skull base chordomas to compare the therapeutic effects of PT and photon RT.

2. Materials and Methods

2.1. Selection Criteria for Meta-Analysis

The review was conducted in accordance with the principles and recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [14]. The study has not been registered. PubMed was searched using the keywords “(chordoma OR chondrosarcoma) AND (radiotherapy OR proton OR carbon) AND (skull OR head)” for articles published from 1990 to 2022. Only articles written in English were included. Two reviewers independently screened all retrieved papers. The process for selecting studies for analysis was as follows: (1) Clinical studies related to chordomas or chondrosarcomas located at the skull base were identified. (2) Articles that reported overall survival (OS) or progression-free survival (PFS) were selected. (3) Studies with ten or more cases per treatment modality were included to ensure robust sample sizes for analysis. (4) Studies in which a single treatment modality accounted for at least 80% of the cases were included. (5) For multiple publications from the same institution covering overlapping periods, only the most recent study was included. Data were extracted for the number of cases, 3- or 5-year OS, 3- or 5-year PFS, late adverse events, age, gender, gross total resection (GTR) rates, tumor volume, total irradiation dose, and treatment modality (PT vs. photon RT or combined photon RT/proton beam therapy (PBT)). If the 3- or 5-year OS and PFS were not specified in the text, these rates were estimated from figures.

2.2. Statistical Analysis

Random effects meta-analyses of 3- and 5-year OS and PFS were performed for each modality, and forest plots were drawn. For studies with missing accuracy data, missing values were imputed using the number of cases, risk set size at each year, and mean dropout rate. Heterogeneity in each meta-analysis was evaluated by I-square statistics. Random-effects meta-regression with modality as an explanatory variable was performed for each outcome to compare the modalities. All analyses were performed using R version 4.3.2 (R Core Team, Vienna, Austria) and its accompanying meta package [15].

3. Results

The selection process and outcomes of the articles are shown in Figure 1. Ultimately, 30 articles met our inclusion criteria [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45]. Among these publications, 17 were focused on PT, 10 on photon RT, and 3 on a combination of photon RT and PBT. All the studies were retrospective except for one prospective study [21]. The details of these articles are shown in Table 1. Forest plots for each modality for 3- and 5-year OS are shown in Figure 2. A meta-analysis of the 30 articles found 3- and 5-year OS rates (PT vs. photon RT or combined photon RT/PBT) of 90.8% (95% CI: 87.4–93.3%) vs. 89.5% (95% CI: 83.0–93.6%), p = 0.6543; 80.0% (95% CI: 75.7–83.6%) vs. 89.5% (95% CI: 83.0–93.6%), p = 0.6787. In the meta-analysis, the 3-year PFS rate for PT group was 71.7% (95% CI: 63.1–78.6%). This rate could not be calculated for photon RT due to insufficient data. Forest plots for each modality for 5-year PFS are shown in Figure 3. The 5-year PFS rates (PT vs. photon RT or photon RT/PBT) were 67.8% (95% CI: 56.5–76.7%) vs. 40.2% (95% CI: 31.6–48.7%), p = 0.0004.
The random-effects meta-regression analysis with modality as an explanatory variable was adjusted primarily for age and gender. This was due to the high rates of missing data for other potential variables, such as GTR and tumor volume, which required exclusion of these variables from the analysis. The results are shown in Table 2. Neither age nor gender were significant factors for any of the indicators. Treatment modality (PT vs. photon RT or photon RT/PBT) was not a significant factor for 3-year OS (p = 0.42) and 5-year OS (p = 0.11), but was a significant factor for 5-year PFS (p < 0.0001). The rate of brain necrosis as a late adverse event is listed in Table 1 for each article. This rate was 8–50% in PT cases, but only 0–4% after photon RT.

4. Discussion

This study is the first meta-analysis comparing the efficacy of PT with photon RT for skull base chordoma. Comparisons of PT with photon RT for chordomas without specifying the site have been reported, but skull base chordoma needs to be treated independently due to the younger age of onset and low rate of complete resection [8]. The biological and physical properties of PT make it useful for skull base chordoma, but the rarity of the disease has prevented randomized comparative studies of PT and photon RT. The current study shows a significant benefit of PT over photon RT for skull base chordoma for 5-year PFS, and PT resulted in 3- and 5-year OS of 90.8% and 80.0%, and 3- and 5-year PFS of 71.7% and 67.8%. These findings show that the challenges posed by the rarity of the disease and the historical reliance on retrospective studies can be overcome using a meta-analysis.
The better PFS after PT compared to photon RT is thought to be due to the total dose and irradiation field. The median total doses in the analysis were 65–78.4 Gy relative biological effectiveness (RBE) for PT, and 14.8–81 Gy (RBE) for photon RT or photon RT/PBT [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45]. Although there were differences in the dose per fraction, the total dose tended to be higher for PT. Additionally, there were differences in the field settings depending on the treatment modality. With Gamma Knife or linear accelerator-based stereotactic radiosurgery and stereotactic radiotherapy (SRS/SRT), the tumor margins are used to define the dose, with a higher dose delivered to the tumor center [35,36]. In contrast, PT planning frequently uses the pre-surgical extent of the tumor and setting of the clinical target volume (CTV) with a 5–10 mm margin to the gross tumor volume (GTV) [17,19,21]. Therefore, the better 5-year PFS with PT may be attributable to the higher total irradiation dose and broader field settings. It was also reported that the high PFS achieved by PT for chordomas is superior in terms of cost-effectiveness [46,47]. Generally, the cost of PT is higher than that of photon RT, but it implies the suppression of costs for reoperations and other procedures. While some reports indicate that PT may not offer significant cost-effectiveness for head and neck cancer due to similar treatment outcomes [48,49], it is considered cost-effective for treating skull base chordomas.
The efficacy of PT may be somewhat offset by the higher rate of brain necrosis after PT. Theoretically, the Bragg peak in PT allows for dose concentration, enabling high-dose delivery to the tumor while minimizing the dose to surrounding normal tissues, as required for skull base chordoma [50]. However, our latest retrospective analysis also identified a 13% occurrence of brain necrosis, with a high total dose found to be a risk factor for brain necrosis [51]. The volume of normal brain exposed to a high dose (over 60 Gy) is known to be a risk factor for brain necrosis, and setting a wider CTV for PT compared to photon RT may also contribute to the occurrence of brain necrosis [52]. In situations where the CTV is curved or U-shaped, intensity-modulated radiation therapy (IMRT) may be effective, and combined photon RT and PBT may also be useful [53]. Particularly for a U-shaped target area, using only passive PT might result in insufficient dose areas to spare the brain, raising concerns about reduced local efficacy [45]. However, this limitation can be overcome with the spot scanning method using intensity-modulated particle beam therapy (IMPT). Indeed, favorable treatment plans using IMPT for skull base chordoma can be created without compromising the dose to the tumor [27,54]. Evidence for use of IMPT is still not widely available, but this method does create superior dose distributions for many organs, not just skull base tumors, compared to IMRT or passive PT [55]. Therefore, as IMPT becomes more accessible, it is likely to facilitate further dose increases, leading to improved treatment outcomes.
The limitations of this study include the rarity of skull base chordoma and the small number of cases treated with photon RT. Due to this rarity, prospective studies are challenging to conduct, and almost all the papers used in this analysis were retrospective studies, which limits the quality of the analysis. In addition, information on dose fractionation, CTV settings, and GTR rates was missing in many papers, which made a thorough analysis difficult. Details of surgical treatment, which play a crucial role in the integrated treatment strategy for chordomas, significantly impact treatment outcomes. Future analyses, including the quality of surgery such as resection rates, are anticipated as results have improved with increased rates of complete resection in our past reports [26,31]. Additionally, performing a subgroup analysis by particle type to examine the differences in biological effects between proton and carbon ion therapy would be of great interest, but due to the lack of studies on carbon ion therapy, this analysis could not be conducted at this time. More detailed analyses will be possible as more treatment outcomes are published.

5. Conclusions

This study shows that particle beam therapy gives higher PFS compared to photon RT for skull base chordoma. However, there is also a tendency for a higher incidence of brain necrosis with particle beam therapy. Further studies are needed to validate these findings.

Author Contributions

T.S. and M.M. authored the main manuscript text. T.S., K.M. and M.N. prepared all Figures and Tables. S.H., K.N., Y.L., Y.O., T.I., M.I., H.F., R.S. and S.S. conducted the literature search and verified the contents of the documents. K.M. performed the statistical analysis. M.M. and H.S. supervised the management of the research and the overall structure of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Strategic Initiatives (S) from the University of Tsukuba.

Informed Consent Statement

Not applicable. This study is a systematic review and meta-analysis of previously published data, and no new data were collected.

Data Availability Statement

The data supporting the findings of this study are available within the article. All data included in this systematic review and meta-analysis were derived from publicly available sources.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Bakker, S.H.; Jacobs, W.C.H.; Pondaag, W.; Gelderblom, H.; Nout, R.A.; Dijkstra, P.D.S.; Peul, W.C.; Vleggeert-Lankamp, C.L.A. Chordoma: A systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival. Eur. Spine J. 2018, 27, 3043–3058. [Google Scholar] [CrossRef]
  2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bone Cancer (Version 1.2024). Available online: https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf (accessed on 23 March 2024).
  3. Barber, S.M.; Sadrameli, S.S.; Lee, J.J.; Fridley, J.S.; Teh, B.S.; Oyelese, A.A.; Telfeian, A.E.; Gokaslan, Z.L. Chordoma-current understanding and modern treatment paradigms. J. Clin. Med. Res. 2021, 10, 1054. [Google Scholar] [CrossRef]
  4. Chanplakorn, P.; Lertudomphonwanit, T.; Homcharoen, W.; Suwanpramote, P.; Laohacharoensombat, W. Results following surgical resection of recurrent chordoma of the spine: Experience in a single institution. World J. Surg. Oncol. 2020, 18, 228. [Google Scholar] [CrossRef] [PubMed]
  5. Bai, J.; Li, M.; Shi, J.; Jing, L.; Zhai, Y.; Zhang, S.; Wang, J.; Zhao, P.; Li, C.; Gui, S.; et al. Mid-term follow-up surgical results in 284 cases of clival chordomas: The risk factors for outcome and tumor recurrence. Neurosurg. Rev. 2022, 45, 1451–1462. [Google Scholar] [CrossRef] [PubMed]
  6. Dial, B.L.; Kerr, D.L.; Lazarides, A.L.; Catanzano, A.A.; Green, C.L.; Risoli, T., Jr.; lazer, D.G.; Goodwin, R.C.; Brigman, B.E.; Eward, W.C.; et al. The role of radiotherapy for chordoma patients managed with surgery: Analysis of the National Cancer Database. Spine 2020, 45, E742–E751. [Google Scholar] [CrossRef]
  7. Hug, E.B.; Pelak, M.; Frank, S.J.; Fossati, P. A review of particle therapy for skull base tumors: Modern considerations and future directions. Int. J. Part. Ther. 2021, 8, 168–178. [Google Scholar] [CrossRef]
  8. Zhou, J.; Yang, B.; Wang, X.; Jing, Z. Comparison of the effectiveness of radiotherapy with photons and particles for chordoma after surgery: A meta-analysis. World Neurosurg. 2018, 117, 46–53. [Google Scholar] [CrossRef] [PubMed]
  9. Zuckerman, S.L.; Bilsky, M.H.; Laufer, I. Chordomas of the skull base, mobile spine, and sacrum: An epidemiologic investigation of presentation, treatment, and survival. World Neurosurg. 2018, 113, e618–e627. [Google Scholar] [CrossRef] [PubMed]
  10. Stacchiotti, S.; Sommer, J.; Chordoma Global Consensus Group. Building a global consensus approach to chordoma: A position paper from the medical and patient community. Lancet Oncol. 2015, 16, e71–e83. [Google Scholar] [CrossRef]
  11. Almefty, K.; Pravdenkova, S.; Colli, B.O.; Al-Mefty, O.; Gokden, M. Chordoma and chondrosarcoma: Similar, but quite different, skull base tumors. Cancer 2007, 110, 2457–2467. [Google Scholar] [CrossRef]
  12. Bohman, L.E.; Koch, M.; Bailey, R.L.; Alonso-Basanta, M.; Lee, J.Y.K. Skull base chordoma and chondrosarcoma: Influence of clinical and demographic factors on prognosis: A SEER analysis. World Neurosurg. 2014, 82, 806–814. [Google Scholar] [CrossRef] [PubMed]
  13. Lu, V.M.; O’Connor, K.P.; Mahajan, A.; Carlson, M.L.; Van Gompel, J.J. Carbon ion radiotherapy for skull base chordomas and chondrosarcomas: A systematic review and meta-analysis of local control, survival, and toxicity outcomes. J. Neurooncol. 2020, 147, 503–513. [Google Scholar] [CrossRef]
  14. Available online: http://prisma-statement.org/prismastatement/checklist.aspx?AspxAutoDetectCookieSupport=1 (accessed on 23 March 2024).
  15. Balduzzi, S.; Rücker, G.; Schwarzer, G. How to perform a meta-analysis with R: A practical tutorial. Evid. Based Ment. Health 2019, 22, 153–160. [Google Scholar] [CrossRef] [PubMed]
  16. Hong, S.; Laack, N.; Mahajan, A.; Choby, G.; O’Brien, E.; Stokken, J.; Janus, J.; Van Gompel, J.J. Analysis of early outcomes of pencil beam proton therapy compared with passive scattering proton therapy for clival chordoma. World Neurosurg. 2023, 171, e644–e653. [Google Scholar] [CrossRef] [PubMed]
  17. Mattke, M.; Ohlinger, M.; Bougatf, N.; Harrabi, S.; Wolf, R.; Seidensaal, K.; Welzel, T.; Röder, F.; Gerum, S.; Ellerbrock, M.; et al. Proton and carbon ion beam treatment with active raster scanning method in 147 patients with skull base chordoma at the Heidelberg ion beam therapy center: A single-center experience. Strahlenther Onkol. 2023, 199, 160–168. [Google Scholar] [CrossRef] [PubMed]
  18. Holtzman, A.L.; Rotondo, R.L.; Rutenberg, M.S.; Indelicato, D.J.; De Leo, A.; Rao, D.; Patel, J.; Morris, C.G.; Mendenhall, W.M. Clinical outcomes following dose-escalated proton therapy for skull-base chordoma. Int. J. Part. Ther. 2021, 8, 179–188. [Google Scholar] [CrossRef]
  19. Koto, M.; Ikawa, H.; Kaneko, T.; Hagiwara, Y.; Hayashi, K.; Tsuji, H. Long-term outcomes of skull base chordoma treated with high-dose carbon-ion radiotherapy. Head Neck 2020, 42, 2607–2613. [Google Scholar] [CrossRef] [PubMed]
  20. Hottinger, A.L.; Bojaxhiu, B.; Ahlhelm, F.; Walser, M.; Bachtiary, B.; Zepter, S.; Lomax, T.; Pica, A.; Weber, D.C. Prognostic impact of the “Sekhar Grading System for Cranial Chordomas” in patients treated with pencil beam scanning proton therapy: An institutional analysis. Radiat. Oncol. 2020, 15, 96. [Google Scholar] [CrossRef] [PubMed]
  21. Iannalfi, A.; D’Ippolito, E.; Riva, G.; Molinelli, S.; Gandini, S.; Viselner, G.; Fiore, M.R.; Vischioni, B.; Vitolo, V.; Bonora, M.; et al. Proton and carbon ion radiotherapy in skull base chordomas: A prospective study based on a dual particle and a patient-customized treatment strategy. Neuro Oncol. 2020, 22, 1348–1358. [Google Scholar] [CrossRef]
  22. Takagi, M.; Demizu, Y.; Nagano, F.; Terashima, K.; Fujii, O.; Jin, D.; Mima, M.; Niwa, Y.; Katsui, K.; Suga, M.; et al. Treatment outcomes of proton or carbon ion therapy for skull base chordoma: A retrospective study. Radiat Oncol. 2018, 13, 232. [Google Scholar] [CrossRef]
  23. Demizu, Y.; Mizumoto, M.; Onoe, T.; Nakamura, N.; Kikuchi, Y.; Shibata, T.; Okimoto, T.; Sakurai, H.; Akimoto, T.; Ono, K.; et al. Proton beam therapy for bone sarcomas of the skull base and spine: A retrospective nationwide multicenter study in Japan. Cancer Sci. 2017, 108, 972–977. [Google Scholar] [CrossRef] [PubMed]
  24. Weber, D.C.; Malyapa, R.; Albertini, F.; Bolsi, A.; Kliebsch, U.; Walser, M.; Pica, A.; Combescure, C.; Lomax, A.J.; Schneider, R. Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiother. Oncol. 2016, 120, 169–174. [Google Scholar] [CrossRef] [PubMed]
  25. McDonald, M.W.; Linton, O.R.; Moore, M.G.; Ting, J.Y.; Cohen-Gadol, A.A.; Shah, M.V. Influence of residual tumor volume and radiation dose coverage in outcomes for clival chordoma. Int. J. Radiat. Oncol. Biol. Phys. 2016, 95, 304–311. [Google Scholar] [CrossRef] [PubMed]
  26. Hayashi, Y.; Mizumoto, M.; Akutsu, H.; Takano, S.; Matsumura, A.; Okumura, T.; Kawabe, T.; Zenkoh, J.; Sakurai, H.; Tsuboi, K. Hyperfractionated high-dose proton beam radiotherapy for clival chordomas after surgical removal. Br. J. Radiol. 2016, 89, 20151051. [Google Scholar] [CrossRef] [PubMed]
  27. Grosshans, D.R.; Zhu, X.R.; Melancon, A.; Allen, P.K.; Poenisch, F.; Palmer, M.; McAleer, M.F.; McGovern, S.L.; Gillin, M.; DeMonte, F.; et al. Spot scanning proton therapy for malignancies of the base of skull: Treatment planning, acute toxicities, and preliminary clinical outcomes. Int. J. Radiat. Oncol. Biol. Phys. 2014, 90, 540–546. [Google Scholar] [CrossRef]
  28. Deraniyagala, R.L.; Yeung, D.; Mendenhall, W.M.; Li, Z.; Morris, C.G.; Mendenhall, N.P.; Okunieff, P.; Malyapa, R.S. Proton therapy for skull base chordomas: An outcome study from the University of Florida Proton Therapy Institute. J. Neurol. Surg. B Skull Base 2014, 75, 53–57. [Google Scholar] [CrossRef]
  29. Ares, C.; Hug, E.B.; Lomax, A.J.; Bolsi, A.; Timmermann, B.; Rutz, H.P.; Schuller, J.C.; Pedroni, E.; Goitein, G. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: First long-term report. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75, 1111–1118. [Google Scholar] [CrossRef] [PubMed]
  30. Weber, D.C.; Rutz, H.P.; Pedroni, E.S.; Bolsi, A.; Timmermann, B.; Verwey, J.; Lomax, A.J.; Goitein, G. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: The Paul Scherrer Institut Experience. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63, 401–409. [Google Scholar] [CrossRef]
  31. Igaki, H.; Tokuuye, K.; Okumura, T.; Sugahara, S.; Kagei, K.; Hata, M.; Ohara, K.; Hashimoto, T.; Tsuboi, K.; Takano, S.; et al. Clinical results of proton beam therapy for skull base chordoma. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60, 1120–1126. [Google Scholar] [CrossRef]
  32. Castro, J.R.; Linstadt, D.E.; Bahary, J.P.; Petti, P.L.; Daftari, I.; Collier, J.M.; Gutin, P.H.; Gauger, G.; Phillips, T.L. Experience in charged particle irradiation of tumors of the skull base: 1977–1992. Int. J. Radiat. Oncol. Biol. Phys. 1994, 29, 647–655. [Google Scholar] [CrossRef]
  33. Roy, A.; Warade, A.; Jha, A.K.; Misra, B.K. Skull base chordoma: Long-term observation and evaluation of prognostic factors after surgical resection. Neurol. India 2021, 69, 1608–1612. [Google Scholar] [CrossRef] [PubMed]
  34. Napieralska, A.; Blamek, S. Intracranial chordoma: Radiosurgery, hypofractionated stereotactic radiotherapy and treatment outcomes. Rep. Pract. Oncol. Radiother. 2021, 26, 764–772. [Google Scholar] [CrossRef] [PubMed]
  35. Cahill, J.; Ibrahim, R.; Mezey, G.; Yianni, J.; Bhattacharyya, D.; Walton, L.; Grainger, A.; Radatz, M.W.R. Gamma knife stereotactic radiosurgery for the treatment of chordomas and chondrosarcomas. Acta Neurochir. 2021, 163, 1003–1011. [Google Scholar] [CrossRef] [PubMed]
  36. Hafez, R.F.A.; Fahmy, O.M.; Hassan, H.T. Gamma knife surgery efficacy in controlling postoperative residual clival chordoma growth. Clin. Neurol. Neurosurg. 2019, 178, 51–55. [Google Scholar] [CrossRef]
  37. Sanusi, O.; Arnaout, O.; Rahme, R.J.; Horbinski, C.; Chandler, J.P. Surgical resection and adjuvant radiation therapy in the treatment of skull base chordomas. World Neurosurg 2018, 115, e13–e21. [Google Scholar] [CrossRef] [PubMed]
  38. Fung, V.; Calugaru, V.; Bolle, S.; Mammar, H.; Alapetite, C.; Maingon, P.; De Marzi, L.; Froelich, S.; Habrand, J.L.; Dendale, R.; et al. Proton beam therapy for skull base chordomas in 106 patients: A dose adaptive radiation protocol. Radiother. Oncol. 2018, 128, 198–202. [Google Scholar] [CrossRef] [PubMed]
  39. Wang, L.; Tian, K.; Ma, J.; Wang, K.; Jia, G.; Wu, Z.; Zhang, L.; Zhang, J. Effect comparisons among treatment measures on progression-free survival in patients with skull base chordomas: A retrospective study of 234 post-surgical cases. Acta Neurochir. 2017, 159, 1803–1813. [Google Scholar] [CrossRef]
  40. Kim, J.W.; Suh, C.O.; Hong, C.K.; Kim, E.H.; Lee, I.J.; Cho, J.; Lee, K.S. Maximum surgical resection and adjuvant intensity-modulated radiotherapy with simultaneous integrated boost for skull base chordoma. Acta Neurochir. 2017, 159, 1825–1834. [Google Scholar] [CrossRef] [PubMed]
  41. Choy, W.; Terterov, S.; Ung, N.; Kaprealian, T.; Trang, A.; DeSalles, A.; Chung, L.K.; Martin, N.; Selch, M.; Bergsneider, M.; et al. Adjuvant stereotactic radiosurgery and radiation therapy for the treatment of intracranial chordomas. J. Neurol. Surg. B Skull. Base 2016, 77, 38–46. [Google Scholar] [CrossRef] [PubMed]
  42. Ahmed, R.; Sheybani, A.; Menezes, A.H.; Buatti, J.M.; Hitchon, P.W. Disease outcomes for skull base and spinal chordomas: A single center experience. Clin. Neurol. Neurosurg 2015, 130, 67–73. [Google Scholar] [CrossRef] [PubMed]
  43. Cho, Y.H.; Kim, J.H.; Khang, S.K.; Lee, J.K.; Kim, C.J. Chordomas and chondrosarcomas of the skull base: Comparative analysis of clinical results in 30 patients. Neurosurg. Rev. 2008, 31, 35–43. [Google Scholar] [CrossRef] [PubMed]
  44. Noël, G.; Feuvret, L.; Calugaru, V.; Dhermain, F.; Mammar, H.; Haie-Méder, C.; Ponvert, D.; Hasboun, D.; Ferrand, R.; Nauraye, C.; et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol. 2005, 44, 700–708. [Google Scholar] [CrossRef] [PubMed]
  45. Terahara, A.; Niemierko, A.; Goitein, M.; Finkelstein, D.; Hug, E.; Liebsch, N.; O’Farrell, D.; Lyons, S.; Munzenrider, J. Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. Int. J. Radiat. Oncol. Biol. Phys. 1999, 45, 351–358. [Google Scholar] [CrossRef] [PubMed]
  46. Sprave, T.; Verma, V.; Sterzing, F.; Bruckner, T.; Hees, K.; Land, B.; Jäkel, O.; Herfarth, K.; Debus, J.; Uhl, M. Cost-effectiveness of carbon ion radiation therapy for skull base chordoma utilizing long-term (10-year) outcome data. Anticancer Res. 2018, 38, 4853–4858. [Google Scholar] [CrossRef] [PubMed]
  47. Austin, A.M.; Douglass, M.J.J.; Nguyen, G.T.; Dalfsen, R.; Le, H.; Gorayski, P.; Tee, H.; Penniment, M.; Penfold, S.N. Cost-effectiveness of proton therapy in treating base of skull chordoma. Australas. Phys. Eng. Sci. Med. 2019, 42, 1091–1098. [Google Scholar] [CrossRef] [PubMed]
  48. Sher, D.J.; Tishler, R.B.; Pham, N.L.; Punglia, R.S. Cost-effectiveness analysis of intensity modulated radiation therapy versus proton therapy for oropharyngeal squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2018, 101, 875–882. [Google Scholar] [CrossRef] [PubMed]
  49. Cheng, Q.; Roelofs, E.; Ramaekers, B.L.T.; Eekers, D.; van Soest, J.; Lustberg, T.; Hendriks, T.; Hoebers, F.; van der Laan, H.P.; Korevaar, E.W.; et al. Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer-comparison of dose, toxicity and cost-effectiveness. Radiother. Oncol. 2016, 118, 281–285. [Google Scholar] [CrossRef]
  50. Schulz-Ertner, D.; Karger, C.P.; Feuerhake, A.; Nikoghosyan, A.; Combs, S.E.; Jäkel, O.; Edler, L.; Scholz, M.; Debus, J. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68, 449–457. [Google Scholar] [CrossRef] [PubMed]
  51. Takahashi, M.; Mizumoto, M.; Oshiro, Y.; Kino, H.; Akutsu, H.; Nakai, K.; Sumiya, T.; Ishikawa, E.; Maruo, K.; Sakurai, H. Risk factors for radiation necrosis and local recurrence after proton beam therapy for skull base chordoma or chondrosarcoma. Cancers 2023, 15, 5687. [Google Scholar] [CrossRef]
  52. McDonald, M.W.; Linton, O.R.; Calley, C.S.J. Dose-volume relationships associated with temporal lobe radiation necrosis after skull base proton beam therapy. Int. J. Radiat. Oncol. Biol. Phys. 2015, 91, 261–267. [Google Scholar] [CrossRef]
  53. Torres, M.A.; Chang, E.L.; Mahajan, A.; Lege, D.G.; Riley, B.A.; Zhang, X.; Lii, M.; Kornguth, D.G.; Pelloski, C.E.; Woo, S.Y. Optimal treatment planning for skull base chordoma: Photons, protons, or a combination of both? Int. J. Radiat. Oncol. Biol. Phys. 2009, 74, 1033–1039. [Google Scholar] [CrossRef] [PubMed]
  54. Basler, L.; Poel, R.; Schröder, C.; Bolsi, A.; Lomax, A.; Tanadini-Lang, S.; Guckenberger, M.; Weber, D.C. Dosimetric analysis of local failures in skull-base chordoma and chondrosarcoma following pencil beam scanning proton therapy. Radiat. Oncol. 2020, 15, 266. [Google Scholar] [CrossRef] [PubMed]
  55. Moreno, A.C.; Frank, S.J.; Garden, A.S.; Rosenthal, D.I.; Fuller, C.D.; Gunn, G.B.; Reddy, J.P.; Morrison, W.H.; Williamson, T.D.; Holliday, E.B.; et al. Intensity modulated proton therapy (IMPT): The future of IMRT for head and neck cancer. Oral. Oncol. 2019, 88, 66–74. [Google Scholar] [CrossRef] [PubMed]
Cancers 16 02569 g001
Figure 1. Flow diagram of study selection for systematic review and meta-analysis.
Figure 1. Flow diagram of study selection for systematic review and meta-analysis.
Cancers 16 02569 g001
Cancers 16 02569 g002
Figure 2. Forest plots of overall survival for skull base chordoma: comparison between particle beam therapy and photon radiotherapy. (A) 3-year OS for particle beam therapy [16,17,19,21,22,23,26,31], (B) 5-year OS for particle beam therapy [16,17,18,19,20,21,22,23,25,26,29,31,32], (C) 3-year OS for photon radiotherapy [34,35,37,43,44], (D) 5-year OS for photon radiotherapy [33,34,35,37,38,40,42,43,44].
Figure 2. Forest plots of overall survival for skull base chordoma: comparison between particle beam therapy and photon radiotherapy. (A) 3-year OS for particle beam therapy [16,17,19,21,22,23,26,31], (B) 5-year OS for particle beam therapy [16,17,18,19,20,21,22,23,25,26,29,31,32], (C) 3-year OS for photon radiotherapy [34,35,37,43,44], (D) 5-year OS for photon radiotherapy [33,34,35,37,38,40,42,43,44].
Cancers 16 02569 g002
Cancers 16 02569 g003
Figure 3. Forest plots of progression-free survival for skull base chordoma: comparison between particle beam therapy and photon radiotherapy. (A) 3-year PFS for particle beam therapy [16,19,22,23,27,31], (B) 5-year PFS for particle beam therapy [16,18,19,20,22,23,31], (C) 5-year PFS for photon radiotherapy [34,37,39,40,41,42,43].
Figure 3. Forest plots of progression-free survival for skull base chordoma: comparison between particle beam therapy and photon radiotherapy. (A) 3-year PFS for particle beam therapy [16,19,22,23,27,31], (B) 5-year PFS for particle beam therapy [16,18,19,20,22,23,31], (C) 5-year PFS for photon radiotherapy [34,37,39,40,41,42,43].
Cancers 16 02569 g003
Table 1. List of selected manuscripts.
Table 1. List of selected manuscripts.
AuthorYearModalitynAge
(Median)		Male
(%)		Tumor
Volume
(Median, cc)		GTR
Rate(%)		Total Dose
(Median, Gy (RBE))		3y
OS
(%)		5y
OS
(%)		5y
PFS
(%)		Brain
Necrosis
(%)
Hong [16]2022Proton324446.9 100.07493936513
Mattke [17]2022Particle1475157.840.40.0 9185 14
Holtzman [18]2021Proton1125268.8 97.373.8 78834
Koto [19]2020Carbon345252.918.70.060.89793.565.750
Hottinger [20]2020Proton1424253.526.396.574 8370
Iannalfi [21]2020Carbon655864.6130.070.49082 30
Iannalfi [21]2020Proton705357.13.527.1749383 30
Takagi [22]2018Particle245641.7170.0659586818
Demizu [23]2017Proton5356 708674.652.8
Weber [24]2016Proton1514357.035.4100.074
McDonald [25]2016Proton395253.824.512.877.4 81.4 18
Hayashi [26]2016Proton195242.11942.178.494.783.2 16
Grosshans [27]2014Proton1043 100.069.8 20
Deraniyagala [28]2014Proton33 78.8 93.974
Ares [29]2009Proton42 42.9 73.5 62 17
Weber [30]2005Proton1839 16.4 74
Igaki [31]2004Proton136138.532.90.0728572.242.215
Castro [32]1994Particle534443.4 100.0729372
Roy [33]2021GKRS15 16 88.9
Napieralska [34]2021SRS/SRT235352.21721.752896943
Cahill [35]2021GKRS155866.71373.3208067 0
Hafez [36]2019GKRS124641.72.70.016 0
Sanusi [37]2018GKRS204755.023.07 14.89595500
Fung [38]2018Combined106 56.6254.873.8 88.3 4
Wang [39]2017GKRS243550.015.80.030.5 42
Kim [40]2017IMRT143921.4 78.667 92.992.90
Choy [41]2016SRS/SRT425357.127.1892.917.8 37
Ahmed [42]2015RT304050.0 81 7331
Cho [43]2008RT193721.1 73.760.284.68040
Noel [44]2005Combined1005360.023 679280.5 1
Terahara [45]1999Combined1154557.446 68.9 88.9
GTR: gross total resection, RBE: relative biological effectiveness, GKRS: gamma knife radiosurgery, SRS: stereotactic radiosurgery, SRT: stereotactic radiotherapy, Combined: Combined photon radiotherapy and proton beam therapy, IMRT: intensity modulated radiation therapy, RT: radiotherapy.
Table 2. Meta-regression analysis of predictive factors for overall survival and progression-free survival.
Table 2. Meta-regression analysis of predictive factors for overall survival and progression-free survival.
FactorsCoefficientSELower CLUpper CLZ Valuep Value
3-year OS
Modality0.2690.331−0.3790.9180.8140.416
Male ratio−0.0100.020−0.0490.029−0.5090.611
Age0.0250.041−0.0560.1060.6090.543
5-year OS
Modality0.3000.187−0.0660.6661.6050.108
Male ratio0.0090.011−0.0120.0300.8190.413
Age0.0040.017−0.0300.0390.2510.802
3-year PFS
Modality0.4412.713−4.8765.7580.1630.871
Male ratio−0.0070.076−0.1560.143−0.0860.932
Age0.0070.068−0.1260.1400.1050.916
5-year PFS
Modality0.9440.2160.5211.3674.372<0.0001
Male ratio−0.0110.010−0.0310.009−1.0660.287
Age0.0080.016−0.0230.0390.5080.612
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Saito, T.; Mizumoto, M.; Oshiro, Y.; Shimizu, S.; Li, Y.; Nakamura, M.; Hosaka, S.; Nakai, K.; Iizumi, T.; Inaba, M.; et al. Systematic Review and Meta-Analysis of Particle Beam Therapy versus Photon Radiotherapy for Skull Base Chordoma: TRP-Chordoma 2024. Cancers 2024, 16, 2569. https://doi.org/10.3390/cancers16142569

AMA Style

Saito T, Mizumoto M, Oshiro Y, Shimizu S, Li Y, Nakamura M, Hosaka S, Nakai K, Iizumi T, Inaba M, et al. Systematic Review and Meta-Analysis of Particle Beam Therapy versus Photon Radiotherapy for Skull Base Chordoma: TRP-Chordoma 2024. Cancers. 2024; 16(14):2569. https://doi.org/10.3390/cancers16142569

Chicago/Turabian Style

Saito, Takashi, Masashi Mizumoto, Yoshiko Oshiro, Shosei Shimizu, Yinuo Li, Masatoshi Nakamura, Sho Hosaka, Kei Nakai, Takashi Iizumi, Masako Inaba, and et al. 2024. "Systematic Review and Meta-Analysis of Particle Beam Therapy versus Photon Radiotherapy for Skull Base Chordoma: TRP-Chordoma 2024" Cancers 16, no. 14: 2569. https://doi.org/10.3390/cancers16142569

APA Style

Saito, T., Mizumoto, M., Oshiro, Y., Shimizu, S., Li, Y., Nakamura, M., Hosaka, S., Nakai, K., Iizumi, T., Inaba, M., Fukushima, H., Suzuki, R., Maruo, K., & Sakurai, H. (2024). Systematic Review and Meta-Analysis of Particle Beam Therapy versus Photon Radiotherapy for Skull Base Chordoma: TRP-Chordoma 2024. Cancers, 16(14), 2569. https://doi.org/10.3390/cancers16142569

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop